@article{JTD18947,
author = {Riyad Tarazi and Mustafa Ridha and Mohammad Shammsah and Khaldoon AlHumood and Jean Tesreni and Mohamed Badawy and Amir Mohamed and Adel Maher},
title = {Left ventricular assist device therapy: the Kuwait experience},
journal = {Journal of Thoracic Disease},
volume = {10},
number = {Suppl 15},
year = {2018},
keywords = {},
abstract = {Background: Heart Failure is an epidemic with a current prevalence of over 5.8 million patients in the USA and almost 23 million patients worldwide, with high associated mortality risks. The severe shortage of donor organs for cardiac transplants and increasing number of heart failure patients has led to the increasing popularity of left ventricular assist device (LVAD) therapy for treatment of end-stage heart failure patients. This paper describes our initial clinical experience with LVAD therapy of heart failure patients at our clinic.
Methods: Ten patients (eight males and two females) with a mean age of 48 years (range, 14–68 years) were implanted with LVADs as bridge to transplantation (BT) or destination therapy (DT) at our clinic between January 2015 and October 2017.
Results: Preliminary results were very promising with 0% 30-day mortality rates and no major surgical complications or LVAD thrombosis.
Conclusions: Such results of LVAD implantation in Kuwait indicate the feasibility of establishing De Novo LVAD programs in low volume LVAD centers (≤10 implants/year) with promising results and offer a new era of hope for treating advanced heart failure patients.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/18947}
}